In October, the Centers for Medicare and Medicaid Services directed carriers to again include three biologics in Medicare Part B coverage. (posted Nov. 19)
Researchers Look for Therapeutic Clues to Sjögrens Syndrome in Neural Pathways
Beyond biologic agents, scientists study cytokines, chemokines, and the interface between inflammatory and neural/secretory pathways
When Will Generic Biologic Drugs Become Commercially Available?
Biosimilars are challenging to produce, but progress is being made
ACR Winter Rheumatology Symposium: Answers to Your Tough Questions about Rheumatic Disease Therapy
Panelists discuss vaccination, biologics and infection, methotrexate, cardiovascular risk, and serial immunoglobulin testing and imaging
ACR Advances Legislation to Increase Patients’ Access to Biologic Drugs to Treat Rheumatoid Arthritis and Other Conditions
The Patients’ Access to Treatments Act of 2013 would prevent insurance companies from tacking on an additional cost-sharing fee for the specialty medications
ACR/ARHP Annual Meeting 2012: Federal Act Aims to Make New Biologic Drugs Available to Rheumatology Patients at a Lower Cost
The Biologics Price Competition and Innovation Act of 2009 would spur the development of products intended to be biosimilar to approved therapies
Rheumatology Drug Updates: Apremilast, Golimumab, and More
Information on new approvals and medication safety rheumatologists need to know
Treat to Target: Rheumatoid Arthritis in Pregnant Patients
A treat-to-target approach to managing rheumatoid arthritis can work even in pregnant women
Drug Updates: Lorcaserin, Acetaminophen, and More
information on new approvals and medication safety
EULAR 2012: Remission the New Normal for Rheumatoid Arthritis
Advances in the rheumatology clinic are promising, two experts say.
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- 13
- Next Page »